ViskaBio is a preclinical stage biotechnology company.  The company develops therapeutic agents  for various types of cancer which function through Immunogenic Cell Death and involve induced lysosome leakage to initiate the processes.  ViskaBio's key technology is therefore known as Lysosome Induced Immunogenic Cell Death or LIICD.